Brought to you by 
Investors put $9mm into Akebia's Series A; add up to $16mm
05 Sep 2012
Executive Summary
Akebia Therapeutics (blood and cardiovascular disease) raised $9mm through its Series A round led by new investors Kearny Venture Partners, Novartis Venture Funds, and Venture Investors, executives from which will take seats on Akebia's board. New buyer Athenian Venture Partners also participated, along with returning backers Triathlon Medical Ventures and Sigvion Capital.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investors put $9mm into Akebia's Series A; add up to $16mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice